Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors

Elizabeth Fox, John M. Maris, Susan L. Cohn, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Diane Medina, Hao Xiong, Andrew Krivoshik, Brigitte Widemann, Peter C. Adamson, Frank M. Balis

Research output: Contribution to journalArticle

Abstract

Purpose: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. Methods: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m2/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. Results: ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t1/2 of 5.1 h. The apparent clearance was 33 ml/min/m2 and was age-independent. The AUC0-∞ increased in proportion to the dose, and at 200 mg/m2 the median AUC 0-∞ was 91 mcg h/ml and the Cave was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min postdose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC0-∞ ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC0-∞ was higher in patients experiencing dose-limiting toxicity. Conclusions: Oral ABT-751 pharmacokinetics was doseproportional and age-independent with minimal intra-and inter-patient variability in children.

Original languageEnglish (US)
Pages (from-to)737-743
Number of pages7
JournalCurrent Microbiology
Volume61
Issue number4
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Neuroblastoma
Pharmacokinetics
Glucuronides
Sulfates
Neoplasms
Biological Availability
Capsules
Suspensions
Water
Area Under Curve
Appointments and Schedules
Parents
High Pressure Liquid Chromatography
ABT751
Urine
Pharmaceutical Preparations
Therapeutics

Keywords

  • Neuroblastoma
  • Pharmacokinetics
  • Tubulin binding agent

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology

Cite this

Fox, E., Maris, J. M., Cohn, S. L., Goodspeed, W., Goodwin, A., Kromplewski, M., ... Balis, F. M. (2010). Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Current Microbiology, 61(4), 737-743. https://doi.org/10.1007/s00280-009-1218-z

Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. / Fox, Elizabeth; Maris, John M.; Cohn, Susan L.; Goodspeed, Wendy; Goodwin, Anne; Kromplewski, Marie; Medina, Diane; Xiong, Hao; Krivoshik, Andrew; Widemann, Brigitte; Adamson, Peter C.; Balis, Frank M.

In: Current Microbiology, Vol. 61, No. 4, 09.2010, p. 737-743.

Research output: Contribution to journalArticle

Fox, E, Maris, JM, Cohn, SL, Goodspeed, W, Goodwin, A, Kromplewski, M, Medina, D, Xiong, H, Krivoshik, A, Widemann, B, Adamson, PC & Balis, FM 2010, 'Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors', Current Microbiology, vol. 61, no. 4, pp. 737-743. https://doi.org/10.1007/s00280-009-1218-z
Fox, Elizabeth ; Maris, John M. ; Cohn, Susan L. ; Goodspeed, Wendy ; Goodwin, Anne ; Kromplewski, Marie ; Medina, Diane ; Xiong, Hao ; Krivoshik, Andrew ; Widemann, Brigitte ; Adamson, Peter C. ; Balis, Frank M. / Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. In: Current Microbiology. 2010 ; Vol. 61, No. 4. pp. 737-743.
@article{d0d0e9f965424d8dbfc8c1c29d119c92,
title = "Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors",
abstract = "Purpose: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. Methods: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m2/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. Results: ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t1/2 of 5.1 h. The apparent clearance was 33 ml/min/m2 and was age-independent. The AUC0-∞ increased in proportion to the dose, and at 200 mg/m2 the median AUC 0-∞ was 91 mcg h/ml and the Cave was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min postdose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC0-∞ ratio was 0.57. Less than 1{\%} of the dose was excreted in urine as parent drug; 13{\%} of the dose was excreted as sulfate metabolite and 10{\%} as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93{\%}, respectively. AUC0-∞ was higher in patients experiencing dose-limiting toxicity. Conclusions: Oral ABT-751 pharmacokinetics was doseproportional and age-independent with minimal intra-and inter-patient variability in children.",
keywords = "Neuroblastoma, Pharmacokinetics, Tubulin binding agent",
author = "Elizabeth Fox and Maris, {John M.} and Cohn, {Susan L.} and Wendy Goodspeed and Anne Goodwin and Marie Kromplewski and Diane Medina and Hao Xiong and Andrew Krivoshik and Brigitte Widemann and Adamson, {Peter C.} and Balis, {Frank M.}",
year = "2010",
month = "9",
doi = "10.1007/s00280-009-1218-z",
language = "English (US)",
volume = "61",
pages = "737--743",
journal = "Current Microbiology",
issn = "0343-8651",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors

AU - Fox, Elizabeth

AU - Maris, John M.

AU - Cohn, Susan L.

AU - Goodspeed, Wendy

AU - Goodwin, Anne

AU - Kromplewski, Marie

AU - Medina, Diane

AU - Xiong, Hao

AU - Krivoshik, Andrew

AU - Widemann, Brigitte

AU - Adamson, Peter C.

AU - Balis, Frank M.

PY - 2010/9

Y1 - 2010/9

N2 - Purpose: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. Methods: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m2/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. Results: ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t1/2 of 5.1 h. The apparent clearance was 33 ml/min/m2 and was age-independent. The AUC0-∞ increased in proportion to the dose, and at 200 mg/m2 the median AUC 0-∞ was 91 mcg h/ml and the Cave was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min postdose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC0-∞ ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC0-∞ was higher in patients experiencing dose-limiting toxicity. Conclusions: Oral ABT-751 pharmacokinetics was doseproportional and age-independent with minimal intra-and inter-patient variability in children.

AB - Purpose: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. Methods: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m2/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. Results: ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t1/2 of 5.1 h. The apparent clearance was 33 ml/min/m2 and was age-independent. The AUC0-∞ increased in proportion to the dose, and at 200 mg/m2 the median AUC 0-∞ was 91 mcg h/ml and the Cave was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min postdose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC0-∞ ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC0-∞ was higher in patients experiencing dose-limiting toxicity. Conclusions: Oral ABT-751 pharmacokinetics was doseproportional and age-independent with minimal intra-and inter-patient variability in children.

KW - Neuroblastoma

KW - Pharmacokinetics

KW - Tubulin binding agent

UR - http://www.scopus.com/inward/record.url?scp=78149286487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149286487&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1218-z

DO - 10.1007/s00280-009-1218-z

M3 - Article

VL - 61

SP - 737

EP - 743

JO - Current Microbiology

JF - Current Microbiology

SN - 0343-8651

IS - 4

ER -